Literature DB >> 12425553

The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review.

Brooks D Cash1, Philip Schoenfeld, William D Chey.   

Abstract

OBJECTIVE: The aim of this study was to determine the pretest probability of organic GI disease and the accuracy of diagnostic tests for organic GI disease in patients who meet symptom-based criteria for irritable bowel syndrome (IBS).
METHODS: After a comprehensive literature search for studies examining the accuracy of diagnostic tests for organic GI disease among patients who meet symptom-based criteria for IBS, two independent observers qualitatively assessed the methodology of selected studies and extracted data. Data on the pretest probability of organic GI disease in this population and the accuracy of currently recommended diagnostic tests were converted to descriptive tables.
RESULTS: Among patients meeting symptom-based criteria for IBS, the pretest probability of inflammatory bowel disease, colorectal cancer, or infectious diarrhea is less than 1%. Currently recommended diagnostic tests rarely identify organic GI disease in patients fulfilling symptom-based criteria for IBS. However, the pretest probability of celiac disease in patients meeting symptom-based criteria for IBS was 10 times higher than the prevalence of celiac disease in the general population.
CONCLUSIONS: There is insufficient evidence to recommend the routine performance of a standardized battery of diagnostic tests in patients who meet symptom-based criteria for IBS. Based upon the increased pretest probability of celiac disease, routine performance of serological tests for celiac disease may be useful in this patient population, though additional study is needed in this area.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12425553     DOI: 10.1111/j.1572-0241.2002.07027.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  53 in total

1.  Diagnosing irritable bowel syndrome: what's too much, what's enough?

Authors:  Susan Lucak
Journal:  MedGenMed       Date:  2004-03-12

Review 2.  Treating irritable bowel syndrome: overview, perspective and future therapies.

Authors:  Michael Camilleri
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

3.  Neural autoantibody evaluation in functional gastrointestinal disorders: a population-based case-control study.

Authors:  Sean J Pittock; Vanda A Lennon; Carissa L Dege; Nicholas J Talley; G Richard Locke
Journal:  Dig Dis Sci       Date:  2010-12-23       Impact factor: 3.199

4.  The treatment of irritable bowel syndrome.

Authors:  Brian E Lacy; Kirsten Weiser; Ryan De Lee
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 5.  Clinical practice. Irritable bowel syndrome.

Authors:  Emeran A Mayer
Journal:  N Engl J Med       Date:  2008-04-17       Impact factor: 91.245

6.  Medical treatment of irritable bowel syndrome.

Authors:  Jason Reina; James W Smith
Journal:  Clin Colon Rectal Surg       Date:  2005-05

7.  The Irritable Bowel Syndrome Outcome Study (IBSOS): rationale and design of a randomized, placebo-controlled trial with 12 month follow up of self- versus clinician-administered CBT for moderate to severe irritable bowel syndrome.

Authors:  Jeffrey M Lackner; Laurie Keefer; James Jaccard; Rebecca Firth; Darren Brenner; Jason Bratten; Laura J Dunlap; Changxing Ma; Mark Byroads
Journal:  Contemp Clin Trials       Date:  2012-07-28       Impact factor: 2.226

8.  New and Emerging Treatment Options for Irritable Bowel Syndrome.

Authors:  Brian E Lacy; William D Chey; Anthony J Lembo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04

Review 9.  New approaches to the medical treatment of irritable bowel syndrome.

Authors:  Driss Berrada; Katia Canenguez; Tony Lembo
Journal:  Curr Gastroenterol Rep       Date:  2003-08

10.  From cytokines to toll-like receptors and beyond - current knowledge and future research needs in irritable bowel syndrome.

Authors:  Oscar Rodríguez-Fandiño; Joselín Hernández-Ruiz; Max Schmulson
Journal:  J Neurogastroenterol Motil       Date:  2010-10-30       Impact factor: 4.924

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.